[go: up one dir, main page]

WO2002036148A3 - Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death - Google Patents

Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death Download PDF

Info

Publication number
WO2002036148A3
WO2002036148A3 PCT/EP2001/012440 EP0112440W WO0236148A3 WO 2002036148 A3 WO2002036148 A3 WO 2002036148A3 EP 0112440 W EP0112440 W EP 0112440W WO 0236148 A3 WO0236148 A3 WO 0236148A3
Authority
WO
WIPO (PCT)
Prior art keywords
caspase
dependent cell
cell death
rip
death
Prior art date
Application number
PCT/EP2001/012440
Other languages
German (de)
French (fr)
Other versions
WO2002036148A2 (en
Inventor
Juerg Tschopp
Nils Holler
Original Assignee
Apoxis Sa
Juerg Tschopp
Nils Holler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoxis Sa, Juerg Tschopp, Nils Holler filed Critical Apoxis Sa
Priority to AU2002215036A priority Critical patent/AU2002215036A1/en
Publication of WO2002036148A2 publication Critical patent/WO2002036148A2/en
Publication of WO2002036148A3 publication Critical patent/WO2002036148A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of physiologically occurring protein, in particular of death receptor ligands or RIP, to initiate the non-caspase-dependent cell death in immune system cells. The invention further relates to compounds, in particular also antibodies, which inhibit the initiation of the non-caspase-dependent cell death, with particular activity in inhibiting the signal transmission path by means of the protein RIP. The invention also relates to a method for identification of the above compounds.
PCT/EP2001/012440 2000-11-02 2001-10-26 Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death WO2002036148A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002215036A AU2002215036A1 (en) 2000-11-02 2001-10-26 Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10054279A DE10054279A1 (en) 2000-11-02 2000-11-02 Use of ligands from death receptors or RIP to trigger caspase-independent cell death and compounds to inhibit caspase-independent cell death
DE10054279.4 2000-11-02

Publications (2)

Publication Number Publication Date
WO2002036148A2 WO2002036148A2 (en) 2002-05-10
WO2002036148A3 true WO2002036148A3 (en) 2003-05-30

Family

ID=7661879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012440 WO2002036148A2 (en) 2000-11-02 2001-10-26 Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death

Country Status (3)

Country Link
AU (1) AU2002215036A1 (en)
DE (1) DE10054279A1 (en)
WO (1) WO2002036148A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI637951B (en) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 Heterocyclic guanamines as kinase inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011793A1 (en) * 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
WO1997015586A1 (en) * 1995-10-23 1997-05-01 Tularik, Inc. Rip: novel human protein involved in tumor necrosis factor signal transduction, and screening assays
US5674734A (en) * 1995-05-18 1997-10-07 President And Fellows Of Harvard College Cell death protein
FR2766713A1 (en) * 1997-08-04 1999-02-05 Bio Merieux PROTEIN FACTOR ASSOCIATED WITH A NEURO-DEGENERATIVE AND / OR AUTO-IMMUNE AND / OR INFLAMMATORY DISEASE
US6114507A (en) * 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011793A1 (en) * 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
US5674734A (en) * 1995-05-18 1997-10-07 President And Fellows Of Harvard College Cell death protein
US6114507A (en) * 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
WO1997015586A1 (en) * 1995-10-23 1997-05-01 Tularik, Inc. Rip: novel human protein involved in tumor necrosis factor signal transduction, and screening assays
FR2766713A1 (en) * 1997-08-04 1999-02-05 Bio Merieux PROTEIN FACTOR ASSOCIATED WITH A NEURO-DEGENERATIVE AND / OR AUTO-IMMUNE AND / OR INFLAMMATORY DISEASE

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BANKI K ET AL: "Elevation of mitochondrial transmembrane potential and reactive oxygen intermediate levels are early events and occur independently from activation of caspases in Fas signaling.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 FEB 1999, vol. 162, no. 3, 1 February 1999 (1999-02-01), pages 1466 - 1479, XP002207346, ISSN: 0022-1767 *
HOLLER N ET AL: "Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.", NATURE IMMUNOLOGY. UNITED STATES DEC 2000, vol. 1, no. 6, December 2000 (2000-12-01), pages 489 - 495, XP001095602, ISSN: 1529-2908 *
JAYANTHI SUBRAMANIAM ET AL: "Dual mechanism of Fas-induced cell death in neuroglioma cells: A role for reactive oxygen species.", MOLECULAR BRAIN RESEARCH, vol. 72, no. 2, 1 October 1999 (1999-10-01), pages 158 - 165, XP002207344, ISSN: 0169-328X *
KAWAHARA ATSUO ET AL: "Caspase-independent cell killing of Fas-associated protein with death domain.", JOURNAL OF CELL BIOLOGY, vol. 143, no. 5, 30 November 1998 (1998-11-30), pages 1353 - 1360, XP002207345, ISSN: 0021-9525 *
LÜSCHEN S ET AL: "Sensitization to death receptor cytotoxicity by inhibition of fas-associated death domain protein (FADD)/caspase signaling. Requirement of cell cycle progression.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 11 AUG 2000, vol. 275, no. 32, 11 August 2000 (2000-08-11), pages 24670 - 24678, XP002207402, ISSN: 0021-9258 *
VERCAMMEN DOMINIQUE ET AL: "Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 5, 5 September 1998 (1998-09-05), pages 919 - 930, XP002207342, ISSN: 0022-1007 *
VERCAMMEN DOMINIQUE ET AL: "Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 9, 4 May 1998 (1998-05-04), pages 1477 - 1485, XP002207343, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
WO2002036148A2 (en) 2002-05-10
DE10054279A1 (en) 2002-05-16
AU2002215036A1 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
WO2003062375A3 (en) Stabilizing polypeptides which have been exposed to urea
WO1999020756A3 (en) Human toll homologues
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2001079461A3 (en) Polypeptides having haloperoxidase activity
WO2002042486A3 (en) Methods for detection of a nucleic acid by sequential amplification
CA2298018A1 (en) Methods and compositions for inhibiting angiogenesis
WO2002032375A3 (en) Uses of monoclonal antibody 8h9
WO2004048517A3 (en) Method for reducing or preventing modification of a polypeptide in solution
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
ZA200203320B (en) Spiro(2H-1-benzopyran-2,4'-piperidine)derivatives as glycine transport inhibitors.
WO2001019956A3 (en) A method for isolation of prostatic epithelial cells from semen
FR2701977B1 (en) Opening roof system, especially for veranda.
WO2001016327A3 (en) Method for producing a channel-forming protein
WO2000050607A3 (en) Goodpasture antigen binding protein
WO2001071942A3 (en) Method and system for detecting signals with multiple antennas
WO2001009384A3 (en) Serial analysis of genetic alterations
WO2002036148A3 (en) Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death
WO1998046632A3 (en) Inhibitors for urokinase receptor
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
WO2002074904A3 (en) Rearranged squamous cell carcinoma antigen genes ii
EP1400807A3 (en) Use of novel stem cell markers for isolation of intestinal stem cells, and use of the intestinal stem cells thus obtained for the preparation of a therapeutical composition
WO2001098523A3 (en) Detection method of genetic recombinant food and detection kit of that
AU7165891A (en) Tumor-specific, cell surface-binding monoclonal antibodies
WO2002086505A3 (en) Intracellular analysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP